Biotricity Expands Cardiac AI Cloud Platform to Enhance Clinical Decision Support

Biotricity, Inc., a Technology-as-a-Service company, announced plans to expand its Cardiac AI Cloud platform. The company's AI automation engine has already shown to boost operational efficiency, resulting in improved margins. The expansion aims to build a cardiac AI clinical model to assist clinicians in decision-making processes. The healthcare AI market is expected to reach $208.2 billion by 2030, with remote patient monitoring (RPM) hitting $96.67 billion. Biotricity anticipates filing for FDA clearance for its new clinical model by year-end.

The proposed AI clinical model will distill critical information to support clinical interventions. Biotricity's collaboration with Google TensorFlow and Amazon Web Services aims to harness big data for developing predictive analytics, potentially improving diagnosis and treatment of cardiac conditions. By analyzing over 500 billion anonymized heartbeats, the AI model is expected to enhance diagnostic accuracy and patient outcomes upon receiving FDA clearance.

Dr. Waqaas Al-Siddiq, Biotricity's CEO, emphasized the company's ambition to revolutionize medical diagnostics and consumer healthcare through its proprietary AI technology. The intended expansion underscores Biotricity's commitment to bridging medical accessibility gaps and pioneering innovations in cardiac care. Investors are directed to the company's website for more detailed information regarding its revenue trajectory and healthcare solutions.